Natural products and synthetic analogs have drawn much attention as potential
therapeutical drugs to treat metabolic syndrome. We reviewed the underlying mechanisms …

Introduction: Peroxisome proliferator-activated receptors (PPARs) are the molecular targets
of hypolipidemic and insulin-sensitizing drugs and implicated in a multitude of processes …

Agonists of the nuclear receptor PPARγ are therapeutically used to combat hyperglycaemia
associated with the metabolic syndrome and type 2 diabetes. In spite of being effective in …

The Peroxisome Proliferator-Activated Receptors-PPARα, PPARγ, and PPARδ--are
members of the nuclear receptor gene family that have emerged as therapeutic targets for …

Overweight and obesity lead to an increased risk for metabolic disorders such as impaired
glucose regulation/insulin resistance, dyslipidemia, and hypertension. Several molecular …

A series of α-alkyl-substituted phenylpropanoic acids was prepared as dual agonists of
peroxisome proliferator-activated receptors alpha and delta (PPARα/δ). Structure–activity …

Type 2 diabetes mellitus (T2DM) is highly prevalent chronic disease. Recently, many
biological targets are discovered for treatment of this disease. The identification of the …

Background Peroxisome proliferator-activated receptors (PPARs) are a class of ligand-
activated nuclear transcription factors, members of the type nuclear receptor superfamily …

PEROXISOME proliferator-activated receptors (PPARs) are ligand-activated transcriptional
factors belonging to superfamily of nuclear hormone receptors related to retinoid, steroid …

Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders
including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart …